Literature DB >> 9014589

Von Willebrand factor in the outcome of temporal arteritis.

M C Cid1, J Monteagudo, J Oristrell, J Vilaseca, L Pallarés, R Cervera, C Font, J Font, M Ingelmo, A Urbano-Márquez.   

Abstract

OBJECTIVE: To determine fluctuation in circulating von Willebrand factor (vWF) in the outcome of patients with temporal arteritis.
METHODS: Plasma vWF antigen concentrations were measured in 65 patients with biopsy proven temporal arteritis at different disease activity stages, in 12 with isolated polymyalgia rheumatica, and in 16 controls. Fourteen temporal arteritis patients underwent serial determinations during the course of their disease.
RESULTS: vWF concentrations were significantly raised in temporal arteritis (mean 220 [arbitrary units], range 96 to 720) and in polymyalgia rheumatica (mean 196, range 103 to 266) compared with healthy controls (mean 98, range 75 to 137) (P < 0.05). Although vWF values tended to be higher in temporal arteritis, no significant differences were found between temporal arteritis and polymyalgia rheumatica patients nor between temporal arteritis patients with ischaemic complications (mean 269, range 130 to 720) and those who presented with polymyalgia rheumatica or constitutional symptoms only (mean 179, range 140 to 220). The highest levels were obtained in patients with associated, mainly infectious, diseases (mean 631, range 240 to 1680). Raised vWF values found in active temporal arteritis patients (mean 220, range 96 to 720) persisted within the first two years after the beginning of treatment (mean 244, range 102 to 510) but tended to normalise in patients in long term remission (mean 143, range 50 to 260).
CONCLUSIONS: Persistent elevation of vWF during early remission of temporal arteritis might represent an endothelial activation status induced by a remaining inflammatory microenvironment rather than a marker of endothelial cell injury. In long term remission, decreasing vWF concentrations might reflect progression of inflammatory lesions to a healing stage.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9014589      PMCID: PMC1010347          DOI: 10.1136/ard.55.12.927

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  14 in total

1.  Differential regulation by cytokines of constitutive and stimulated secretion of von Willebrand factor from endothelial cells.

Authors:  E M Paleolog; D C Crossman; J H McVey; J D Pearson
Journal:  Blood       Date:  1990-02-01       Impact factor: 22.113

2.  Investigation of plasma von Willebrand factor and circulating platelet aggregating activity in mitomycin C-related hemolytic-uremic syndrome.

Authors:  J Monteagudo; A Pereira; S Roig; J C Reverter; A Ordinas; R Castillo
Journal:  Am J Hematol       Date:  1990-01       Impact factor: 10.047

3.  Immunohistochemical analysis of lymphoid and macrophage cell subsets and their immunologic activation markers in temporal arteritis. Influence of corticosteroid treatment.

Authors:  M C Cid; E Campo; G Ercilla; A Palacin; J Vilaseca; J Villalta; M Ingelmo
Journal:  Arthritis Rheum       Date:  1989-07

4.  Temporal arteritis and polymyalgia rheumatica. Clinical and biopsy findings.

Authors:  P Fauchald; O Rygvold; B Oystese
Journal:  Ann Intern Med       Date:  1972-12       Impact factor: 25.391

5.  Factor VIII related antigen in the assessment of vasculitis.

Authors:  A D Woolf; G Wakerley; T B Wallington; D G Scott; P A Dieppe
Journal:  Ann Rheum Dis       Date:  1987-06       Impact factor: 19.103

6.  von Willebrand factor as a marker of injury to the endothelium in inflammatory vascular disease.

Authors:  A D Blann
Journal:  J Rheumatol       Date:  1993-09       Impact factor: 4.666

7.  Factor VIII activity and factor VIII-related antigen in infants with viral bronchiolitis.

Authors:  D Mazzone; A Fichera; G Praticò; F Sciacca
Journal:  N Engl J Med       Date:  1984-11-08       Impact factor: 91.245

8.  Increased von Willebrand factor antigen in the plasma of patients with vasculitis.

Authors:  S R Nusinow; A B Federici; T S Zimmerman; J G Curd
Journal:  Arthritis Rheum       Date:  1984-12

9.  Factor VIII-von Willebrand factor in giant cell arteritis and polymyalgia rheumatica.

Authors:  S T Persellin; T M Daniels; L J Rings; F J Kazmier; E J Bowie; G G Hunder
Journal:  Mayo Clin Proc       Date:  1985-07       Impact factor: 7.616

10.  Elevation of von Willebrand factor is independent of erythrocyte sedimentation rate and persists after glucocorticoid treatment in giant cell arteritis.

Authors:  A B Federici; R I Fox; L R Espinoza; T S Zimmerman
Journal:  Arthritis Rheum       Date:  1984-09
View more
  4 in total

Review 1.  Spectrum of giant cell vasculitis.

Authors:  N Mohan; G Kerr
Journal:  Curr Rheumatol Rep       Date:  2000-10       Impact factor: 4.592

Review 2.  Recent advances in temporal arteritis.

Authors:  Carol Redillas; Seymour Solomon
Journal:  Curr Pain Headache Rep       Date:  2003-08

Review 3.  Epidemiology and optimal management of polymyalgia rheumatica.

Authors:  P Labbe; P Hardouin
Journal:  Drugs Aging       Date:  1998-08       Impact factor: 4.271

Review 4.  Role of von Willebrand factor in venous thromboembolic disease.

Authors:  Alison Michels; David Lillicrap; Michael Yacob
Journal:  JVS Vasc Sci       Date:  2021-10-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.